MedaData offers AI-powered prescribing decision support software that analyzes patient data against medical guidelines and drug interaction databases. The platform provides clinicians with evidence-based medication recommendations to improve patient safety and treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Medication errors contribute to adverse patient outcomes and increased healthcare costs. Current prescribing practices often lack the personalized, data-driven insights necessary to select the most effective and safest medication for individual patients.
Solution
MedaData provides an AI-enabled Prescribing Decision Support Software designed to enhance clinical decision-making. The platform analyzes de-identified patient data against established medical guidelines and drug interaction databases to offer evidence-based medication recommendations. This approach aims to improve patient safety and treatment efficacy by facilitating personalized prescribing. The software's initial application focuses on identifying eligible patients for antiviral treatments like Paxlovid, incorporating information on drug interactions and the CYP enzyme system.
Target Audience
The primary users are clinicians and healthcare providers who require advanced decision support tools to optimize medication selection for their patients.
Features
- AI-driven analysis of patient data for personalized medication recommendations.
- Integration of up-to-date clinical guidelines and drug interaction information.
- Specific module for identifying eligibility for antiviral medications, including Paxlovid.
- Data processing utilizes de-identified patient information to maintain privacy.
- Supports analysis of the CYP enzyme system for drug metabolism considerations.
- Provides evidence-based advice to clinicians at the point of care.